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ABSTRACT This manuscript describes an enantioselective synthesis of cephalostatin 1. Key steps of 
this synthesis are a unique methyl group selective allylic oxidation, directed C-H hydroxylation of a 
sterol at C12, Au(I)-catalyzed 5-endo-dig cyclization and a kinetic spiroketalization. 
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Introduction 
An important property of modern anti-cancer therapeutics is the selective killing of cancer cells over 
normal cells.  One approach to achieve selectivity is “synthetic lethality,”
1 involving combination of a 
mutation, only present in cancer cells, and a small molecule, resulting in selective cell killing of the cells 
bearing the mutation.  Since many genetic mutations have been identified in tumor cells, a challenge is 
to discover small molecules that selectively target cells harboring these mutations. 
We have become interested in the therapeutic potential and cellular target of cephalostatin 1 (1), a 
natural product that may be synthetic lethal with the p16 tumor suppressor gene. In a bioinformatics 
comparison of the cytotoxicity profiles of ~43,000 small molecules with cell lines bearing altered p16, 1   2 
emerged as the compound with the highest correlation, suggesting that it may be selectively cytotoxic to 
cells  with  altered  p16.
2  The  p16  gene  encodes  cyclin-dependent  kinase  inhibitor  2A  (CDKN2A  or 
Ink4a), a tumor suppressor protein that blocks cell proliferation by binding to and inhibiting the kinase 
activity of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6).
2 In cells, both 
CDK4 and CDK6 each form active complexes with cyclin D that phosphorylate Rb (the retinoblastoma 
protein), allowing progression through the G1-S phase of the cell cycle.  If CDKN2A is inactive due to a 
mutation or lack of expression, tumor cells can progress uncontrollably through the G1-S phase of the 
cell cycle.
3 Since p16 is among the most frequently mutated genes in human tumor cells, 1 may be a 
uniquely selective anti-cancer therapeutic, and elucidation of its unknown cellular target may reveal new 
ways to achieve synthetic lethality with small molecules. 
Cephalostatin 1 was first reported in 1988 as a potent growth inhibitory marine natural product.
4 The 
average GI50 of 1 against the NCI-60, a collection of 60 human cancer cell lines, is 1.8 nM.
5 Three other 
molecules,  ritterazine  B  (2),
6  OSW-1  (3)
7  and  schweinfurthin  A  (4)
8  have  cytotoxicity  patterns 
resembling 1, suggesting that all three compounds share similar mechanisms.
9 The cellular target and 
mechanism of 1 (or 2-4) has not been elucidated, although an increasing amount of research is being 
focused on these issues.
10  
The unusually large and complex structure of 1 has been the target of many synthesis studies, with 
one synthesis reported by Fuchs.
11 Due to the small quantities of 1 available from natural sources, only 
through  synthesis  will  sufficient  amounts  of  1  (and  analogs)  be  available  to  address  questions 
surrounding its potential synthetic lethality with p16, elucidation of its cellular target and mechanism, 
and determination of its efficacy in vivo.  This manuscript reports our synthesis of 1 (Figure 1), enabling 
us to answer the questions posed above surrounding its biological activity.   3 
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Figure 1. Cephalostatin 1, ritterazine B, OSW-1.  Three antiproliferative natural products with similar 
cytotoxicity patterns. 
Synthesis of the western half of cephalostatin 1 (5).   
Our  synthesis  plan  involved  construction  of  the  eastern  and  western  portions  of  1,  followed  by 
unsymmetrical pyrazine formation following the reactions developed by Heathcock
12 and Fuchs.
11a,13  
The C22 spiroketal of 5 (Scheme 1) is in a thermodynamically favorable configuration, meaning that its 
stereochemistry  can  be  established  by  acid-catalyzed  equilibration.
14  Hecogenin  acetate  (6),  an 
inexpensive  plant-derived  steroid  that  is  available  in  kilogram  quantities,
15  is  used  as  the  starting 
material for our synthesis of the western half since it has handles for most of the functionality of 5, 
especially oxygenation at C12.  Compound 6 was also used by others for their synthesis studies on 1.  
With  6  as  a  starting  point  for  synthesis  of  5,  we  need  to  rearrange  the  spiroketal,  oxidize  C23, 
deoxygenate C16, install a C14-C15 olefin, and most challenging, oxidize the unactivated C18 angular 
methyl group (see Scheme 1).  Our plan was to generate lumihecogenin acetate (7) by photolysis of 6, a   4 
reaction first described by Bladon.
16 Selective oxidation of C18 of 7 to generate 8 followed by Prins 
cyclization would deliver 9. Compound 9 would then be converted to 5.  We recognized that 7 is the 
only intermediate in our synthesis in which C18 is activated (allylic), and therefore we focused on 
methods to selectively oxidize the allylic methyl group.  This is a significant challenge since the olefin 
of 7 is tetrasubstituted and there are four other allylic hydrogens (see blue H’s), two methines and one 
methylene.  We require an oxidation that is selective for the C18 methyl group and tolerant of highly 
hindered double bonds, boundary conditions that exclude many of the known allylic oxidation reactions. 
 
Scheme 1. Synthesis plan for 5 requiring a C18 methyl group-selective allylic oxidation of 7. 
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The synthesis of 5 begins with the known conversion of 6 to 7 (Scheme 2).
16 Attempts to perform 
allylic oxidation of C18 on either aldehyde 7 or the protected alcohol at C18 were unsuccessful.  As   5 
expected,  SeO2  led  to  hydroxylation  of  the  C15  methylene.    Radical  halogenations  were  poorly 
regioselective and the hindered double bond was inert to transition metal-catalyzed allylic oxidation 
reactions. 
 
Scheme  2.  Selective  C18  methyl  group-selective  allylic  oxidation  involving  ene  reaction,  [2,3]-
sigmatropic rearrangement, and oxidation
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a Conditions: (a) hν, 1,4-dioxane, 25 ºC; (b) 4-phenyl-1,2,4-triazoline-3,5-dione, dichloroethane, 25 
ºC,  61%  2  steps;  (c)  NaOAc,  DMF,  100  ºC,  69%;  (d)  CH(OMe)3,  TsOH•H2O,  MeOH,  25  ºC;  (e) 
PhI(OAc)2, MeCN/H2O, 0 ºC, 64% 2 steps; (f) NaBH4, MeOH, 0 ºC, 88%; (g) NaH, DMF, 0 ºC; allyl 
bromide, 25 ºC , 93%; (h) PPTS, acetone, 25 ºC ; (i) BF3⋅OEt2, PhMe, 0 ºC, 61% 2 steps; (j) Ac2O, pyr., 
DMAP, 25 ºC. 
Ultimately, an unusual allylic oxidation of C18 was achieved.  It was discovered that treatment of 7 
with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD, 10), a potent eneophile, lead directly to 11 achieving   6 
selective functionalization of the C18 methyl group.  Selective activation of the C18 methyl, via an 
apparent ene reaction, combined with formation of a seven-membered aminal. This transformation may 
in fact be directed by the C12 aldehyde since the corresponding C12 dimethyl acetal reacted to form a 
PTAD adduct with abstraction of a C15 proton.  One explanation for the selective activation of C18 in 
this reaction involves initial formation of a zwitterionic adduct (18) between PTAD (10) and aldehyde 7 
(Scheme 3).  This species could participate in an intramolecular aza-Prins reaction via intermediate 19.  
Close proximity between the C12 alkoxide and the C18 methyl group in 19 could explain the selective 
proton abstraction at C18.  Alternatively, PTAD could add to the C12 aldehyde via its carbonyl and 
engage in an ene reaction, although inspection of molecular models appears to preclude this mechanism 
due to lack of required orbital overlap.  Finally, an ene reaction may occur between 10 and 7 followed 
by hemiaminal formation. 
Treatment of 11 with sodium acetate induced opening of the hemiaminal followed by apparent [2,3]-
sigmatropic  rearrangement,  affording  allylic  N-Ph  urazole  12  (Scheme  3).  Protection  of  the  C12 
aldehyde as its dimethyl acetal was followed by oxygenation of C18 by treatment of 13 with PhI(OAc)2, 
affording aldehyde 14.  In this reaction, the N-N bond is oxidized to N=N.  Tautomerization, addition of 
water, and release of the urazole affords 14.  Allylation of the primary hydroxyl group, followed by acid 
catalyzed acetal hydrolysis set the stage for C-ring closure which was accomplished by treatment with 
BF3⋅OEt2 (Scheme 2).  Finally, acetylation of the secondary alcohol provided 17. 
 
 
 
 
 
 
 
   7 
Scheme 3. Proposed mechanism of the selective aza-Prins reaction, [2,3]-sigmatropic rearrangement, 
and urazole oxidative hydrolysis 
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Starting with compound 17, allyl group-selective oxidative olefin cleavage, aldehyde reduction and 
protection of the resulting primary hydroxyl afforded 20 (Scheme 4).  Next, the atoms comprising the 
spiroketal were removed starting with application of a modified Marker degradation.
17 Treatment of 20 
with trifluoroacetyl trifluoromethanesulfonate (TFAT) opened the F-ring, giving E-ring dihydrofuran 
21.    Oxidative  cleavage  of  the  cyclic  enol  ether  provided  the  corresponding  ketoester,  which  was 
subjected  to  DBU-promoted  elimination.    The  product,  dienone  22  underwent  1,4  reduction  under 
platinum-catalyzed hydrosilylation conditions, affording the saturated methyl ketone 23 as a 4:1 mixture 
of  β/α-methyl  ketone  stereoisomers.    After  removal  of  the  TBDPS  ether,  and  separation  of  the 
diastereomers, the undesired C17 α-methyl ketone was equilibrated in favor of the β-diastereomer.  
Oxidation of the C23 primary hydroxyl preceded an intramolecular aldol reaction to afford enal 26. 
 
 
 
 
Scheme 4. Conversion of 17 to cephalostatin 1 western half (5)
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a Conditions: (a) OsO4, NaIO4, 2,6-lutidine, 1,4-dioxane/H2O, 25 ºC; (b) NaBH(OAc)3, PhH/AcOH, 0 
ºC;  (c)  TBDPSCl,  Im.,  DMAP,  CH2Cl2,  25  ºC,  74%  4  steps;  (d)  trifluoroacetyl 
trifluoromethanesulfonate, 2,6-tert-butyl-4-methyl-pyridine, CH2Cl2, -78 ºC, then PPTS, CH2Cl2, 40 ºC; 
(e) PCC, CH2Cl2, 25 ºC; (f) DBU, CH2Cl2, 43% 3 steps; (g) (HMe2Si)2O, H2PtCl6, PhMe, 25 ºC; (h) 
TBAF, AcOH, THF, 25 ºC, 51% 2 steps; (i) DMSO, i-PrNEt2, SO3•pyr, CH2Cl2, 25 ºC; (j) piperidine, 
AcOH, 25 ºC, 75% 2 steps; (k) 1-methoxy-1- tert-butyldimethylsilyloxyethene, LiClO4, CH2Cl2, 27β: 
51%, 27α: 18%; (l) TBAF, THF, 25 ºC, 100%; (m) Ph3P, DIAD, chloroacetic acid, THF, 25 ºC, 69%; 
(n) HDTC, 2,6-lutidine, AcOH, 25 ºC, 80%;  (o) TBDPSCl, Im., DMAP, CH2Cl2, 25 ºC, 93%; (p) 
MeMgBr, Et2O, 25 ºC; (q) TPAP, NMO, CH2Cl2, 25 ºC, 69% 2 steps; (r) PhSeBr, pyridine, CH2Cl2, -78 
ºC to 0 ºC, 92%; (s) AIBN, Bu3SnH, toluene, 100 ºC, 100%; (t) CSA, DCE, 83 ºC, 78%. 
Installation  of  the  C24-C25  fragment  of  the  incipient  F-ring  was  accomplished  by  way  of  a 
Mukaiyama aldol reaction.  Thus, treatment of aldehyde 26 with the enolsilane of methyl acetate in the 
presence of lithium perchlorate delivered a 3:1 mixture of diastereomers favoring the undesired 23-(S)-
stereoisomer  (27β).    Unfortunately,  extensive  efforts  to  override  the  substrate’s  inherent  facial 
selectivity for aldol addition were met with failure.  Attempts at Mukaiyama aldol addition with other 
catalysts,  including  chiral  catalysts,  afforded  product  mixtures  favoring  23-(S)-configured  products.  
Likewise, chiral auxiliary-based acetate equivalents reacted to give predominantly adducts with the 
undesired  23-(S)  stereochemistry.    Removal  of  the  TBS  group  from  27β,  Mitsunobu  reaction  with 
chloroacetic acid, hydrolysis of the chloroacetate, silylation of the C23 secondary carbinol and addition 
of excess MeMgBr afforded 28 after oxidation with TPAP/NMO. 
Since  the  spiroketal  of  5  is  known  to  be  under  thermodynamic  control,  we  expected  mild  acid 
treatment  of  28  to  furnish  the  F-ring  while  establishing  the  desired  (S)-stereochemistry  at  C20.    9 
However,  in  the  presence  of  camphorsulfonic  acid,  28  cyclized  to  give  a  spiroketal  with  20-(R) 
stereochemistry.    Surprisingly,  the  observed  product  results  from  protonation  of  the  more  hindered 
concave face of the dihydropyran E-ring.  This result is in contrast to a similar reaction reported by 
Fuchs in which protonation of a compound closely related to 28 (except that the C14-C15 double bond 
was saturated) afforded the desired C20-(S) stereochemistry.
14  
This outcome was corrected by a two-step bromoetherification/reductive debromination sequence.  
Bromoetherification of 28 with phenylselenyl bromide afforded 29.  Reductive dehalogenation of 29 
delivered 30 as a single diastereomer with hydrogen atom addition occurring from the convex face.  To 
complete the preparation of the cephalostatin western half 5, C22 was epimerized by treatment of 30 
with camphorsulfonic acid in refluxing dichloroethane. 
Synthesis of the cephalostatin 1 eastern half (31).  
The  E  and  F  rings  of  the  eastern  half  of  cephalostatin  1  consist  of  a  5,5-spiroketal  in  a 
thermodynamically unfavorable configuration at C22 requiring kinetic control for its formation (Scheme 
5, 31).  The spiroketal in the natural C22-(S) configuration exhibits a single anomeric effect, while the 
unnatural C22-(R) configuration permits additional stabilization due to a second anomeric effect.  To 
form the 5,5-spiroketal, we planned to induce cyclopropane opening on 32 concurrent with irreversible 
attack by the C25 hydroxyl group on the less hindered β–face of the incipient oxonium ion, which 
would simultaneously give rise to the desired configurations of both the C22 spiroketal and the C21 
methyl group.  Rather than starting with hecogenin acetate (6) to make use of its C12 oxygenation as for 
the western half of 1, we thought it more expedient to hydroxylate the C12 position of the steroid trans-
androsterone (34) by a remote C-H oxidation process (see Scheme 5, 34).  To increase convergency of 
the synthesis of 32, the remote oxidation of 34 would be followed by Sonogashira cross coupling with 
alkyne 33, which comprises seven of the eight carbons of the E,F-rings spiroketal. 
 
 
   10 
Scheme 5. Synthesis plan for 31 requiring a remote oxidation of 34 and Sonogashira coupling with 33 
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Our synthesis of alkyne 33 began with the known diol 35 (two steps from 3-methyl-3-buten-1-ol, 89% 
yield, 96% ee).
18  We protected the primary hydroxyl as a TBDPS ether, removed the PMP group by 
CAN oxidation, and protected both hydroxyl groups of the resulting 1,3-diol as TMS ethers to afford 37 
in 80% yield over three steps (Scheme 6).  The Swern reagent chemoselectively converted the TMS 
ether  of  the  primary  carbinol  directly  into  aldehyde  38.    Carreira  alkynylation
19  with 
ethynyltrimethylsilane favored the desired (4R)-propargyl alcohol by 32:1 and provided it in 57% yield 
from 37.  The secondary carbinol was protected as a TBS ether to deliver 39 and the alkynyl TMS was 
removed with AgNO3 and 2,6-lutidine,
20 affording alkyne 33. 
 
Scheme 6. Synthesis of alkyne 33 from known diol 35
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a Conditions: (a) TBDPSCl, imidazole, DMF; (b) CAN, CH3CN, H2O, 0 
oC; (c) TMSCl, imidazole, 
DMF,  80%  3  steps;  (d)  oxalyl  chloride,  DMSO,  Et3N,  CH2Cl2,  -78 
oC;  (e)  Zn(OTf)2,  (+)-N-
methylephedrine,  Et3N,  ethynyltrimethylsilane,  toluene,  40 
oC,  57%  2  steps;  (f)  TBSCl,  imidazole, 
DMAP, CH2Cl2; (g) AgNO3, THF, H2O, EtOH, 2,6-lutidine, 93% 2 steps.   11 
Our  synthesis  of  the  steroid-derived  Sonogashira  coupling  partner  began  with  the  commercially 
available steroid trans-androsterone 34 (Scheme 7).  Utilizing the procedure of Schönecker for the 
hydroxylation of unactivated C-H bonds,
21 we treated the steroid with 2-(aminomethyl)pyridine and 
catalytic TsOH to form imine 40 in 89% yield.  Treatment of 40 with Cu(OTf)2, benzoin, and Et3N in 
acetone to generate Cu(I), followed by the addition of molecular oxygen resulted in hydroxylation at the 
unactivated C12 position.  Hydrolytic workup provided diol 41 as a single diastereomer in 25% yield.  
Acetylation with Ac2O/pyridine and treatment with PhN(Tf)2/KHMDS led to vinyl triflate 43 in 88% 
yield. 
 
Scheme 7. Synthesis of vinyl triflate 43 from commercially-available trans-androsterone 34 by remote 
oxidation at C12
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a Conditions: (a) 2-aminomethylpyridine, TsOH, toluene, 110 ºC, 89%; (b) Cu(OTf)2; benzoin, Et3N, 
acetone; O2; HCl; NH4OH, 25%; (c) Ac2O, pyridine, 97%; (d) PhN(Tf)2, KHMDS, THF, -78 
oC to 25 
ºC, 91%. 
Pd-catalyzed Sonogashira coupling of vinyl triflate 43 and alkyne 33 provided enyne 44 in 94% yield 
(Scheme 8).  Sharpless dihydroxylation of the enyne proceeded with complete stereocontrol to install 
the α-hydroxyl at C17.  Further oxidation with benzeneseleninic anhydride
22 converted the cis-diol into 
unstable α-hydroxy cyclopentenone 45 in fairly low yield despite extensive efforts toward optimization.   12 
 
Scheme 8. Completion of the synthesis of the eastern half of cephalostatin 1
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a Conditions: (a) 33, (Ph3P)4Pd, CuI, iPr2EtN, DMF, 94%; (b) (DHQ)2PHAL, K2CO3, K3Fe(CN)6, 
MeSO2NH2  ,  K2OsO4•2H2O,  tBuOH,  H2O,  95%;  (c)  (PhSeO)2O,  K2CO3,  toluene,  110  ºC;  (d) 
NaBH(OAc)3, THF, 65 
oC, 36% 2 steps; (e) Ph3PAuCl, AgBF4, THF, 88%; (f) CH2I2, Et2Zn, toluene, 0 
ºC; (g) PPTS, CH2Cl2, MeOH, 73% 2 steps; (h) NBS, THF, -10 ºC; (i) Bu3SnH, AIBN, toluene, 110 ºC; 
(j) TMSOTf, pyridine, 65% 3 steps; (k) KHCO3, MeOH, H2O, 65 
oC; (l) HCrO4, Et2O, CH2Cl2, 0 ºC, 
88% 2 steps. 
Treatment of the enone 45 with NaBH(OAc)3 resulted in C17 hydroxyl-directed reduction to trans-
diol 46. Diol 46 underwent Au(I)-catalyzed 5-endo-dig cyclization
23 to provide dihydrofuran 47 in 88% 
yield.  It is worth noting the ease with which the Au(I)-catalyzed cyclization takes place on what is a 
highly hindered internal alkyne. Again using the C17 hydroxyl as a directing group, Simmons-Smith 
conditions stereoselectively converted the dihydrofuran 47 to cyclopropane 48 with an α configuration.  
Deprotection  of  the  C25  hydroxyl  with  PPTS  delivered  spiroketalization  substrate  32  as  a  single 
diastereomer in 73% yield from 47.  Treatment of 32 with Zeise’s dimer [{(η
2-C2H4)PtCl2}2], resulted in 
quantitative spiroketalization;
24 however, the undesired C22-(R) spiroketal stereoisomer was favored by 
a 13:1 ratio.  This may be due to HCl generated during the reaction and attempts to buffer the reaction 
with nitrogenous bases inhibited spiroketalization. We later discovered that oxidative spiroketalization 
using NBS in THF furnished a separable mixture of bromomethylene spiroketals favoring the desired 
C22-(S) isomer 49 by a 5:1 ratio.   Lack of equilibration in this reaction is due to the neutral reaction   13 
conditions. Debromination of 49 by Bu3SnH/AIBN followed by silylation of the extremely hindered 
C17 hydroxyl using neat pyridine/TMSOTf delivered 50 in 65% yield from 49.  Selective hydrolysis of 
the C3 acetate (the C12 acetate is shielded by the C17 OTMS group) followed by Brown-modified 
Jones oxidation
25 provided 31, the eastern half of cephalostatin 1, in 88% yield over two steps. 
Completion of a synthesis of cephalostatin 1.  
To  prepare  the  A  rings  of  western  half  5  and  eastern  half  31  for  pyrazine  coupling,  we  used  a 
sequence of reactions developed by Fuchs
11b (Scheme 9). Bromination α to the C3 ketone and azidation 
with tetramethylguanidinium azide in EtNO2 provided 52 from 5 and 54 from 31.  The C3 ketone of 54 
was converted to methoxime 55, and Staudinger reduction of the azide to an amine gave pyrazine 
coupling partner 56.  52 and 56 were treated with polyvinylpyridine and Bu2SnCl2 in refluxing benzene 
to provide protected cephalostatin 1 (57) along with a trace of recovered 56.  Global deprotection of the 
silyl groups and the C12 acetate was affected by TBAF in refluxing THF to afford cephalostatin 1 in 
47% yield from 52. 
 
 
 
 
 
Scheme 9. Pyrazine coupling and completion of the synthesis of cephalostatin 1
a   14 
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a Conditions: (a) PhMe3NBr3, THF, 0 ºC; (b) tetramethylguanidinium azide, EtNO2, 83% 2 steps; (c) 
PhMe3NBr3, THF, 0 ºC; (d) tetramethylguanidinium azide, EtNO2, 78% 2 steps; (e) NH2OMe•HCl, 
pyridine/CH2Cl2; (f) PPh3, THF/H2O, 0 to 25 
oC, 77% 2 steps; (g) polyvinylpyridine, Bu2SnCl2, benzene, 
80 ºC; (h) TBAF, THF, 47% 2 steps. 
In conclusion, an enantioselective synthesis of cephalostatin 1 has been achieved.  In the course of our 
synthesis of the western half, a unique methyl group-selective allylic oxidation was developed. PTAD 
underwent  selective  functionalization  of  the  C18  methyl  group,  apparently  directed  by  a  proximal 
aldehyde.  Subsequent [2,3]-sigmatropic rearrangement and oxidative hydrolysis of the resulting urazole 
led to a C18 aldehyde that could not be produced using other methods.  This allylic functionalization 
sequence may be useful in other systems where conventional methods fail.  Key steps in the eastern half 
synthesis include a remote C-H hydroxylation of C12, Sonogashira coupling between a steroid-derived 
vinyl triflate and an alkyne containing most of the atoms of the E and F rings, a Au(I)-catalyzed 5-endo-
dig cyclization, and a kinetic spiroketalization by cyclopropane ring opening.  Our goal is to uncover the 
cellular target of cephalostatin 1 and explore its therapeutic potential.  This synthesis is a first step 
toward achieving these goals. 
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